Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: Frequency and possible cause of cefazolin treatment failure

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3437-3441

  Nannini, Esteban C ^a   Stryjewski, Martin E ^b,c   Singh, Kavindra V ^e   Bourgogne, Agathe ^e   Rude, Tom H ^d   Corey, G Ralph ^d   Fowler Jr , Vance G ^d   Murray, Barbara E ^e  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CEMIC   (Argentina)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFAMANDOLE; CEFAZOLIN; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; INOCULATION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CEFAMANDOLE; CEFAZOLIN; HUMANS; METHICILLIN; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

EID: 67749135640     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00317-09     Document Type: Article

References (30)

1. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, T. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation 111:e394-e433.
2. Bruns, W., and H. Keppeler. 1987. Extracellular and membrane-bound beta lactamase of Staphylococcus aureus: their importance for the expression of penicillin resistance. J. Med. Microbiol. 23:133-139.
3. Bryant, R. E., and R. H. Alford. 1977. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 237:569-570.
4. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th edition. CLSI document M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Fernandez-Guerrero, M. L., and M. de Gorgolas. 2005. Cefazolin therapy for Staphylococcus aureus bacteremia. Clin. Infect. Dis. 41:127.
6. Fowler, V. G., M. W. Scheld, and A. Bayer. 2005. Endocarditis and intravascular infections, p. 975-1022. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 6th ed., vol. 1. Elsevier Churchill Livingstone, Philadelphia, PA.
7. Gold, J. A., J. J. McKee, and D. S. Ziv. 1973. Experience with cefazolin: an overall summary of pharmacologic and clinical trials in man. J. Infect. Dis. 128(Suppl.):S415-S422.
8. Kernodle, D. S., D. C. Classen, J. P. Burke, and A. B. Kaiser. 1990. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 263:961-966.
9. Kernodle, D. S., D. C. Classen, C. W. Stratton, and A. B. Kaiser. 1998. Association of borderline oxacillin-susceptible strains of Staphylococcus aureus with surgical wound infections. J. Clin. Microbiol. 36:219-222.
10. Kernodle, D. S., P. A. McGraw, C. W. Stratton, and A. B. Kaiser. 1990. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants. Antimicrob. Agents Chemother. 34:420-425.
11. Kernodle, D. S., C. W. Stratton, L. W. McMurray, J. R. Chipley, and P. A. McGraw. 1989. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J. Infect. Dis. 159:103-108.
12. Malathum, K., K. V. Singh, G. M. Weinstock, and B. E. Murray. 1998. Repetitive sequence-based PCR versus pulsed-field gel electrophoresis for typing of Enterococcus faecalis at the subspecies level. J. Clin. Microbiol. 36:211-215.
13. Miro, J. M., I. Anguera, C. H. Cabell, A. Y. Chen, J. A. Stafford, G. R. Corey, L. Olaison, S. Eykyn, B. Hoen, E. Abrutyn, D. Raoult, A. Bayer, and V. G. Fowler, Jr. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514.
14. Nannini, E. C., K. V. Singh, and B. E. Murray. 2003. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis. 37:1194-1198.
15. Quinn, E. L., D. Pohlod, T. Madhavan, K. Burch, E. Fisher, and F. Cox. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128(Suppl.):S386-S389.
16. Richmond, M. H. 1975. Immunological techniques for studying beta-lactamases. Methods Enzymol. 43:86-100.
17. Rosdahl, V. T. 1986. Penicillinase production in Staphylococcus aureus strains of clinical importance. Dan. Med. Bull. 33:175-184.
18. Rubinstein, E., G. R. Corey, M. E. Stryjewski, J. L. Vincent, J. Y. Fagon, M. H. Kollef, M. M. Kitt, and H. D. Friedland. 2008. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., abstr. K-530. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
19. Shuford, J. A., K. E. Piper, M. Hein, A. Trampuz, J. M. Steckelberg, and R. Patel. 2006. Lack of association of Staphylococcus aureus type A beta-lactamase with cefazolin combined with antimicrobial spacer placement prosthetic joint infection treatment failure. Diagn. Microbiol. Infect. Dis. 54:189-192.
20. Singh, K. V., T. M. Coque, G. M. Weinstock, and B. E. Murray. 1998. In vivo testing of an Enterococcus faecalis efaA mutant and use of efaA homologs for species identification. FEMS Immunol. Med. Microbiol. 21:323-331.
21. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by grampositive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
22. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
23. Stryjewski, M. E., L. A. Szczech, D. K. Benjamin, Jr., J. K. Inrig, Z. A. Kanafani, J. J. Engemann, V. H. Chu, M. J. Joyce, L. B. Reller, G. R. Corey, and V. G. Fowler, Jr. 2007. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44:190-196.
24. Takenouchi, T., Y. Utsui, S. Ohya, and T. Nishino. 1994. Role of betalactamase of methicillin-susceptible Staphylococcus aureus in resistance to first-generation oral cephems both in vitro and in vivo. J. Antimicrob. Chemother. 34:909-920.
25. Voladri, R., M. Tummuru, and D. Kernodle. 1996. Structure-function relationships among wild-type variants of Staphylococcus aureus beta-lactamase: importance of amino acids 128 and 216. J. Bacteriol. 178:7248-7253.
26. Voladri, R. K., and D. S. Kernodle. 1998. Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:3163-3168.
27. Williams, D. N., R. B. Gustilo, R. Beverly, and A. C. Kind. 1983. Bone and serum concentrations of five cephalosporin drugs. Relevance to prophylaxis and treatment in orthopedic surgery. Clin. Orthop. Relat. Res. 1983:253-265.
28. Wilson, K. 1994. Preparation of genomic DNA from bacteria, p. 2.4.1-2.4.2. In F. M. Ausubel, R. E. Kingston, D. M. David, J. G. Scidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Green Publishing Associates, Brooklyn, NY.
29. Wilson, W. R., A. W. Karchmer, A. S. Dajani, K. A. Taubert, A. Bayer, D. Kaye, A. L. Bisno, P. Ferrieri, S. T. Shulman, and D. T. Durack. 1995. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 274:1706-1713.
30. Zygmunt, D. J., C. W. Stratton, and D. S. Kernodle. 1992. Characterization of four beta-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36:440-445.